Reviewing Abliva AB (publ) (OTCMKTS:NEVPF) and Palatin Technologies (PINK:PTNT)

Abliva AB (publ) (OTCMKTS:NEVPF) and Palatin Technologies (PINK:PTNT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Institutional and Insider Ownership

11.5% of Palatin Technologies shares are owned by institutional investors. 7.1% of Palatin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Abliva AB (publ) and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abliva AB (publ)	N/A	-117.92%	-102.44%
Palatin Technologies	N/A	N/A	-365.57%

Analyst Ratings

This is a summary of current ratings for Abliva AB (publ) and Palatin Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abliva AB (publ)	0	0	0	0	0.00
Palatin Technologies	0	0	1	0	3.00

Palatin Technologies has a consensus price target of $350.00, indicating a potential upside of 6,150.00%. Given Palatin Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Palatin Technologies is more favorable than Abliva AB (publ).

Earnings and Valuation

This table compares Abliva AB (publ) and Palatin Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abliva AB (publ)	$10,000.00	1,128.43	-$9.01 million	N/A	N/A
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61

Abliva AB (publ) has higher earnings, but lower revenue than Palatin Technologies.

Risk & Volatility

Abliva AB (publ) has a beta of -1.18, suggesting that its stock price is 218% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Summary

Palatin Technologies beats Abliva AB (publ) on 8 of the 11 factors compared between the two stocks.

About Abliva AB (publ)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.